Daniel Rea

University Hospitals Birmingham NHS Foundation Trust

Mindelsohn Way

Edgbaston

Birmingham , B15 2TH

United Kingdom

SCHOLARLY PAPERS

2

DOWNLOADS
Rank 19,542

SSRN RANKINGS

Top 19,542

in Total Papers Downloads

5,183

TOTAL CITATIONS

41

Scholarly Papers (2)

1.

Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

Number of pages: 25 Posted: 23 Aug 2021
University of Birmingham - NIHR Birmingham Biomedical Research Centre and Institute of Cancer and Genomic Sciences, University of Glasgow, Imperial College London, University of Birmingham, University of Birmingham, University of Birmingham, University of Birmingham, University of Birmingham, University of Birmingham, University of Oxford, University of Oxford, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Birmingham - Institute of Cancer and Genomic Sciences, Imperial College London, University of Oxford, NHS Foundation Trust - St. Georges University Hospitals, University Hospitals Birmingham NHS Foundation Trust, University of Leeds, University of Liverpool - NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Glasgow - Institute of Infection, Immunity and Inflammation, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, Imperial College London, Oxford University Hospitals NHS Foundation Trust, University of Glasgow and University of Glasgow
Downloads 5,149 (3,532)
Citation 40

Abstract:

Loading...

2.

Directing Therapy with Circulating Tumor DNA Analysis in Advanced Breast Cancer: The PlasmaMATCH Trial

Number of pages: 217 Posted: 12 Aug 2020
Institute of Cancer Research (ICR) - Breast Cancer Now Research Centre, Institute of Cancer Research (ICR) - Breast Cancer Now Research Centre, Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), The Christie NHS Foundation Trust - The NIHR Manchester Clinical Research Facility, University of Glasgow - Institute of Cancer Sciences, University of Cambridge - Cancer Research UK Cambridge Institute, University College London - University College London Hospitals NHS Foundation Trust, Government of the United Kingdom - Royal Devon and Exeter Hospital, University of Edinburgh - Edinburgh Cancer Centre, University Hospitals Bristol - University Hospitals Bristol NHS Foundation Trust, Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, Government of the United Kingdom - Velindre University NHS Trust, Government of the United Kingdom - Weston Park Hospital, Government of the United Kingdom - Royal Marsden NHS Foundation Trust, Government of the United Kingdom - Royal Marsden NHS Foundation Trust, University of Bonn - Institute of Pathology, Institute of Cancer Research (ICR) - Breast Cancer Now Research Centre, Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), University Hospitals Birmingham NHS Foundation Trust, University of Edinburgh - Edinburgh Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, Independent Cancer Patients' Voice, Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU) and Government of the United Kingdom - Breast Unit
Downloads 34 (878,768)
Citation 1

Abstract:

Loading...

Advanced Breast Cancer; Circulating Tumor DNA; ctDNA; ctDNA Testing; ctDNA Sequencing; Targeted Sequencing: Targeted Treatment; Targeted Therapies; Mutation-directed Therapies; ESR1 Mutation; HER2 Mutation; AKT1 Mutation; ERPositive Breast Cancer; ER-Negative Breast Cancer; PTEN Mutation; HER2 Inhib